• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

New risk factors provide challenges day and night


A growing body of evidence points to diurnal fluctuations in intraocular pressure and nocturnal low ocular perfusion pressure as risk factors in the development and progression of glaucoma.

"Our understanding of both diurnal and nocturnal IOP has been expanded by recent studies," said Dr. Chaglasian.

He cited a number of studies including several population-based clinical trials in both North America and Europe during his talk.

Unfortunately, there is no instrument or clinical device to provide optometrists with 24-hour IOP information, but clinical studies have demonstrated that IOP is higher at night in almost all patients-those with normal eyes as well as those with glaucoma-and Dr. Chaglasian said that must be considered as a mechanism of progression.

"As far as management of these risk factors, I suggest monitoring patients' blood pressure often, and being aware of 24-hour fluctuations and diurnal pressure changes as a possible underlying etiology in glaucoma suspects and glaucoma patients who are getting worse despite presenting with controlled pressure in the office," he said.

To control nighttime IOP, Dr. Chaglasian said it's important to remember that medical therapies that have similar diurnal efficacy may have different nocturnal efficacy. He suggested prescribing prostaglandin analogs and carbonic anhydrase inhibitors.

"Prostaglandin analogs are well recognized as being superior to other classes for lowering and flattening the diurnal IOP curve," he said. "There's also some suggestion that carbonic anhydrase inhibitors control IOP well at night. Either agent is preferable to beta blockers, which don't provide nocturnal coverage for IOP reduction."

Remember OPP

Compounding the difficulty of controlling nocturnal IOP is mounting evidence from multiple types of studies that suggest low OPP is an important risk factor for the development of glaucoma and glaucoma progression, Dr. Chaglasian said.

OPP is the differential between arterial blood pressure and IOP. Studies have shown that using the simple formula of subtracting the patient's IOP from his or her diastolic blood pressure can help identify patients at risk.

"If this diastolic [OPP] drops below 50, studies show that there's a significant increase in risk of the patient developing glaucoma, or having a greater risk of progression of the disease," Dr. Chaglasian said.

He added that a number of large studies provide strong evidence among different populations for the relationship between vascular deficits and the prevalence, incidence, and progression of glaucoma.

"Low blood pressure at night, coupled with high IOP when the patient is in a supine position, compromise OPP and place the optic nerve head at risk for damage," he said. "It makes sense to use systemic blood pressure medications in the morning to minimize the risk of nocturnal hypotension, to use IOP lowering drugs to reduce IOP while sleeping, and to avoid IOP meds that lower systemic blood pressure at night, such as beta blockers and alpha agonists."

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.